Sign in with Google. Opens in new tab
ENTITY

Lonza Group (LONN SW)

30
Analysis
Health CareSwitzerland
Lonza is a global partner to the pharmaceutical, biotech and nutrition markets. The company works with healthcare customers to develop, manufacture and commercialize medical treatments and technologies to treat patients against a range of diseases. Founded in the Swiss Alps, Lonza now operates across Europe, North America, South America, Asia and Oceania.
more
bullishWuXi XDC Cayman
16 Nov 2023 00:09

WuXi XDC Cayman IPO Trading - Strong Subscription Rates Heading into Listing

WuXi XDC Cayman (1877628D HK) raised US$470m in its Hong Kong IPO. In our previous notes, we looked at the company’s past performance and...

Logo
525 Views
Share
bearishLonza Group
13 Nov 2023 16:53

Lonza Group (LONN SW): Customer Driven Events Are Impacting Near-Term Performance

​Lonza's biologics division saw 1% decline in revenue in 1H23 due to lower demand for COVID-19 vaccines, leading to reduced sales growth...

Logo
402 Views
Share
bullishWuXi XDC Cayman
07 Nov 2023 18:15

WuXi XDC IPO Valuation Analysis: Premium Multiples Reflect 100%+ Top-Line Growth

WuXi XDC set terms for an upcoming IPO in Hong Kong. The company plans to raise ~$470M, and the IPO price range implies a market cap of ~$3B at the...

Logo
660 Views
Share
bullishWuXi XDC Cayman
07 Nov 2023 03:39

WuXi XDC Cayman IPO - Decent Upside from IPO Range, Bulk of the Deal Taken up by Marquee Investors

WuXi XDC Cayman (1877628D HK) is looking to raise US$470m in its Hong Kong IPO. In this note, we will look at the deal dynamics and share our final...

Logo
707 Views
Share
bullishWuXi XDC Cayman
06 Nov 2023 22:08

WuXi XDC IPO Preview: The Rapid Rise of The Business In The Global ADC and Bioconjugate Market

WuXi XDC filed to go public in Hong Kong. A rare combination of explosive growth and profitability makes the IPO attractive for investors

Logo
500 Views
Share
x